1 JOSEPH D. TARIMAN, PhD, RN, ANP-BC, FAAN Curriculum Vitae CONTACT INFORMATION ...

22 Pages·2016·0.17 MB·English

1
JOSEPH D. TARIMAN, PhD,RN,ANP-BC, FAAN
CurriculumVitae
CONTACT INFORMATION
Schoolof Nursing
College of Science and Health
DePaul University
990 W. Fullerton Avenue Suite 3000
Chicago, IL60614
USA
Telephone: [phone]
Fax: [phone]
Email:[email protected]
EDUCATION
Ph.D. in Nursing Science University of Washington-Seattle, 2011
Major: Biobehavioral Nursingand Health Systems (BNHS)
Dissertation Title: Treatment Decision Making in Older Adults
Diagnosed with Active Myeloma
Post-MSN NP Certificate University of Miami-Coral Gables, FL, 2001
Major: Adult Health
Master of Arts in Nursing Cebu Doctors’ University, Philippines, 1993
Major: Medical-Surgical Nursing
Thesis: Incidence of Nosocomial Infections in the ICU Unit
Bachelor of Science in Nursing University of the Visayas, Philippines, 1991
Major: Generalist Nursing
ACADEMIC APPOINTMENTS
Assistant Professor DePaul University, 2014-present
Adult-Gerontology Nurse Practitioner
Doctor of Nursing PracticeProgram
Adjunct Assistant Professor Cebu Doctors' University. Philippines-1991-1995;2015-present
. PhD in Nursing Science Program , Biostatistics
Predoctoral Fellow University of Washington-Seattle, 2009-2011
NIH-National Research Service Award
1F31NR011124-01A1
2
Predoctoral Research Fellow University of Washington-Seattle, 2006-2009
Biobehavioral Nursing ResearchNR007106-NIH/NINR
ADMINISTRATIVE APPOINTMENTS
DePaul Faculty Representative September 2015-present
National Hartford Center of Gerontological Nursing Excellence
DePaul FacultyRepresentative September 2015-present
American Association of Colleges of Nursing Jonas Scholarship Program
TEACHING EXPERIENCE
DePaul University:Doctoral LevelResearchCoursesat DePaul University, NSG 600, 601, 602, 603
Graduate Level Courses onAdvanced Pathophysiology (NSG 428), Advanced Gerontological Nursing(NSG
479),Applied Pharmacology and Pathophysiology (NSG 429),Advanced Pharmacology(NSG484)
Pharmacotherapeutic Implications for Older Adults (NSG 555)
Cebu Doctors' University:AdvancedManagement/Executive Development,Applied Epidemiology,
Multivariate Statistics and Biostatistics atCebu Doctors' University PhD in Nursing Scienceand Medicine
Program
BSN Program-Fundamentals of Nursing and Medical-Surgical Nursing
20 YEARS OFCLINICAL EXPERIENCE______________________________________________
IV Home Infusion RN August 1995-1997
Total Care Services, Miami, FL
Director of Staff Development & Training June 1997-September 1999
American Health care Services, Miami Lakes, FL
Clinical Nurse II September 1999-May 2001
University of Miami Hospitals Oncology Unit, Miami, FL
Nurse Manager May 2001-May 2002
University of Chicago Hospitals
Bone Marrow Transplant Unit, Chicago, IL
Lead Nurse Practitioner May 2002-June2006; June 2010-January 2014
Northwestern University Myeloma Program, Chicago, IL
3
GRANTS,SPONSORED RESEARCHAND CONTRACTS
Grants (Funded)
Tariman, J. D.,"Characterization of novel biomarkers for fatigue in elderly patients receiving
immunomodulatory or proteasome inhibitor chemotherapy," Sponsored by DPU-RFU
Collaborative Pilot Grant, DePaul University, $86,000.00.
Active: December 2015-July 2017
Role: Principal Investigator. Ongoing.
Pre-Doctoral Grants(Funded)
Pre-Doctoral Fellow, Ruth L. Kirschstein National Service Award funded by the National
Institute of Health, National Institute of Nursing Research, Individual Fellowship Grant
#1F31NR011124-01A1. Funding: $49,800 2009-2011.
Project title: Treatment decision making in older adults newly diagnosed with multiple
myeloma; September 2009–March 2011 (18 months full support).
Role: Principal Investigator
Sponsors: Barbara Cochrane, PhD, RN, FAAN (University of Washington) & Donna L. Berry, PhD,
RN, FAAN (University of Washington and Dana Farber Cancer Institute).Completed.
Pre-Doctoral Fellow, Ruth L. Kirschstein National Service Award funded by the National
Institute of Health, National Institute of Nursing Research, Institutional Grant #T32 -
Training in Biobehavioral Nursing Research; September 2006 – September 2008 (full
support). $75,000 2006-2009.
Mentor: Donna L. Berry, PhD, RN, FAAN
Research residency: Electronic Self Report Assessment for Cancer (ESRA-C). Completed.
Sponsored Research
Tariman, J.D., "Development and testing of Shared Decision Making Question for Nurses (SDMQ-
Nurses). Funded: Chicago Chapter Oncology Nursing Society, Local, $6,000. (August2016-
August 2018). Ongoing.
Tariman, J. D., "An Internet-Based Survey on Health Maintenance and Preventive Care Patterns
in Myeloma Patients," Sponsored by International Myeloma Foundation, Private, $1,500.00.
(June 2013-September 2014).
Role: Principal Investigator. Completed.
Tariman, J. D., "The role of the nurse in the era of cancer treatment shared decision making
process"Sponsored byChicago Chapter Oncology Nursing Society, Private, $3,000.
(September 2014-October 2016).
Role: PrincipalInvestigator. Completed.
4
Tariman, J.D., "QOL post-ASCT among elderly adults with multiple myeloma. Chicago
Oncology Nursing Society Research Grant, October 2002 to October 2005, ($1,500
Co-Principal Investigator with Judith Paice, PhD, FAAN, RN). Completed.
Pharmaceutical (Industry-Sponsored) and Cooperative Sponsored Research
Two Primary Roles as Co-Investigator in the Research Team:
A. Assessment and monitoring of side effects and serious adverse events.
B. Authorized designee to sign case report forms and documentation of response to investigational
therapy (Form 1572).
1. DRUG54767414MMY2002 An Open-label, Multicenter, phase 2 Trial Investigating the Efficacy
and Safety of Daratumumab in Subjects with Multiple Myeloma Who HaveReceived at Least 3
Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are Double Refractory to a
Proteasome Inhibitor and an IMiD. October 2013-2014.
2. CHART MC12R42 Racial Disparities in Myeloma. June 2013-2014.
3. NCI USC11M01 Risk Factors for Multiple Myeloma in African Americans, A Genome Wide
Association Study (GWAS). June 2011-2014.
4. DRUG FRF4998GAn Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of
Escalating Doses of DFRF4539A in Patients with Relapsed or Refractory Multiple Myeloma.
January 2012-December 2014.
5. DRUG MFG4809GAn Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics
of Escalating Doses of MFGR1877S in Patients with Relapsed or Refractory t(4;14)-Positive
Multiple Myeloma. August 2010-January 2012.
6. DRUG 2011-02 Carfilzomib Myeloma Access Program (C-MAP) study for Relapsed Refractory
Myeloma–January 2012-August 2012.
7. DRUG PX-171-010 A Phase 2, Open Label Study of Carfilzomib Maintenance Therapy in Subjects
Previously Enrolled in Carfilzomib Treatment Protocols. July 2010-July 2012
8. SWOG 0777: A Randomized Phase III Trial of CC5013 (Lenalidomide, NSC-703813) and Low Dose
Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose
Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma
Without an Intent for Immediate Autologous Stem Cell Transplant. June 2010-October 2013.
9. NU00X3 Pathology Core Facility Bio Banking. June 2010-December 2014.
10. CC-5013-MM-016Lenalidomide Expanded Access Program for Patients with Relapsed and/or
refractory MM. November 2005-March 2006.
11. ECOG4A03 A Randomized Phase III Study of CC-5013 plus Dexamethasone versus CC-5013 plus
Low Dose Dexamethasone in Multiple Myeloma with Thalidomide plus Dexamethasone Salvage
Therapy for Non-Responders–May 2005 to March 2006.
12. An Open-Label Phase II Trial of Motexafin Gadolinium (MGD) in Patients with Relapsed or
Refractory Multiple Myeloma. Sub-Investigator–November 2004 to March 2006.
13. CC-5013-MM-014: A Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and
Efficacy of Single-Agent CC-5013 in Subjects with relapsed and Refractory Multiple Myeloma.
Sub-Investigator–July 2003 to March 2006.
14. CC-5013-MM-009: A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled
Study of CC-5013 Plus Dexamethasone in Previously Treated Subjects with Multiple Myeloma.
Sub-Investigator–May 2003 to June 2004.
5
15. E1A00: A Randomized Phase III trial of Thalidomide Plus Dexamethasone Versus Dexamethasone
in Newly Diagnosed Multiple Myeloma. Sub-Investigator–January 2003 to May 2004.
16. M34102-052: An Open-Label, Randomized Study to Assess Two different Strategies of
Combining Dexamethasone with Velcade in Patients with Relapsed Multiple Myeloma who Have
Failed Four or More Lines of Therapy. Sub-Investigator–January 2003 to May 2003.
17. M34101-040: An International, Non-Comparative, Open Label Study of PS-341 Administered to
Patients with Multiple Myeloma Who Experienced Relapsed or Progressive Disease After
Receiving At Least Four Previous Treatment Regimens or Experienced Progressive Disease After
Receiving Dexamethasone in Millennium Protocol M34101-039. Sub-Investigator–February
2002 to May 2003.
18. An International, Multi-Center, Randomized, Open Label Study of PS-341 Versus High-Dose
Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Protocol M34101-
039. Sub-Investigator–February 2002 to May 2003.
19. A phase II, Open Label, Extension Study to Provide PS-341 to PatientsWho Previously
Participated in a PS-341 Clinical Study and Who May Benefit from Re-Treatment with or
Continuation of PS-341 Therapy Protocol M34101-029. Sub-Investigator–February 2002 to
April 2003.
20. A phase II, Open Label Study of PS-341 in Patients with Relapsed/Refractory Myeloma Protocol
M34101-025. Sub-Investigator–February 2002 to June 2002.
21. Randomized Phase III Study of Dexamethasone With or Without Genasense (Bcl-2 Antisense
Oligonucleotide) in Patients with Relapsed or Refractory Multiple Myeloma Protocol GMY302.
Sub-Investigator–February 2002 to May 2003.
Contract
Tariman, J. D., "AACN Jonas Scholarship," FacultyAdviser; Sponsored by American Association of
Colleges of Nursing, Private, $22,500.00 for 2 years(Fall2016-Summer2018).
PUBLICATIONS
Note:The symbolGdenotes DePaul graduate student co-authorsand mentees.
Peer ReviewedOriginalResearch Papers:
GTalbott, C.,Watson,L.,Tariman, J.,Sorenson,M.(2016). Clinical chatter: Every nurse informed.
Journal of ClinicalNursing.doi: 10.1111/jocn.13620. [Epub ahead of print].
Tariman, J.D.,GMehmeti, E., GSpawn, N.,GMcCarter, S., Bishop-Royse, J.,Garcia, I., ... Szubski,
K. (2016).Oncology nursing andshared decision-makingfor cancertreatment.Clinical Journal of
Oncology Nursing, 20(5), 560-563.
McCarter, S.P.,Tariman, J.D., Spawn, N., Mehmeti, E., Bishop-Royse, J., Garcia, I.,... Szubski,
K.(2016).Barriers & promoters to participation in the era of shared decision-making
G G G
process.Western Journal ofNursing Research.pii: 0193945916650648. [Epub ahead of print].
6
Tariman, J. D., Gleason, C., Faiman, B., Doss, D., Catamero, D., Bishop-Royse, J.,... Lonial, S.
(2016). Lack of health maintenance examinations and risk in myeloma patients.Cancer
Medicine. doi: 10.1002/cam4.716
Tariman, J. D.,&Szubski, K. (2015).The evolving role of the nurse during cancer treatment
decision making process: A literature review.Clinical Journal of Oncology Nursing, 19,(5), 548-
56.
Tariman, J. D.,Doorenbos, A., Schepp, K. G., Singhal, S., & Berry, D. L. (2015). Top information
need priorities of older adults newly diagnosed with active myeloma.Journal of the Advanced
Practitioner in Oncology, 6(1), 14-21.
Lee, Y.-M., Florez, E. A.,Tariman, J.D.,GMcCarter, S., Riesche, L. (2015). Factors related to
sexual behaviors and sexual education programs for Asian-American adolescents.Applied
Nursing Research, 28, 222-228.
Tariman, J. D., Doorenbos, A., Schepp, K. G., Becker, P., &Berry, D. L. (2014). Patient, physician
and contextual factors are influential in the treatment decision making of older adults newly
diagnosed with symptomatic myeloma.Cancer Treatment Communications, 2(2-3), 34-47.DOI:
http://dx.doi.org/10.1016/j.ctrc.2014.08.003
Tariman, J. D.,Doorenbos, A., Schepp, K. G., Singhal, S., & Berry, D. L. (2014). Older adults
newly diagnosed with symptomatic myeloma want to participate in treatment decision making.
Oncology Nursing Forum, 41(4), 411-19.
Tariman, J. D.,Doorenbos, A., Schepp, K. G., Singhal, S.,&Berry, D. L. (2014). Information needs
priorities inpatientsdiagnosed withcancer: Asystematicreview.Journal of the Advanced
Practitioner inOncology, 2014(5), 115-22.
Heuck, C. J.,Mehta, J.,Bhagat, T.,Gundabolu, K,Yu, Y.,Khan, S.,Chrysofakis, G.,Schinke, C.,
TarimanJ., et al (2013).Myeloma is characterized bystage-specificalterations in DNA
methylationthat occurearly duringmyelomagenesis.Journal of Immunology, 190(6), 2966-75.
doi: 10.4049/jimmunol.1202493.
Tariman, J. D.,Berry, D. L., Cochrane, B., Doorenbos, A., & Schepp, K. G. (2012). Physician,
patient, and contextual factors affecting treatment decisions in older adults with cancer and
models of decision making: A literature review.Oncology Nursing Forum, 39(1), E70-E83.
Faiman, B., Miceli, T. S., Richards, T.,Tariman, J. D.(2012). Survey of experiences of an e-
mentorship program: Part II.Clinical Journal of Oncology Nursing, 16(1),50-54.
Tariman, J. D.,Berry, D. L., Halpenny, B., Wolpin, S.,&Schepp, K. (2011). Validation and testing
of the Acceptability E-scale for web-based patient reported outcomes in cancer care.Journal of
Applied Nursing Research, 24(1), 53-58.
7
Tariman, J. D.,Berry, D. L., Cochrane, B., Doorenbos, A., Schepp, K. (2010). Preferred and actual
level of participation during health care decision-making in persons with cancer: A systematic
review.Annals of Oncology, 21(6), 1145-51.
Rehwaldt, M.,Wickham,R., Purl, S.,Tariman, J., Blendowski, C., Shott, S., et al. (2009).Self-care
strategies to cope with taste changes after chemotherapy.Oncology Nursing Forum,36(2), E47-
56.
Chanan-Khan, A.A., Kaufman, J.L., Mehta, J., Richardson, P.G., Miller, K.C., Lonial, S., Munshi, N.
C., Schlossman, R.Tariman, J.,et al., (2007). Activity and safety of bortezomib in multiple
myeloma patients with advanced renal failure: A multicenter retrospective study.Blood, 109(6),
2604-06.
Refereed ReviewArticles
Tariman, J.D. (2016).Changes in cancer treatment: Mabs,mibs,mids,nabs andnibs.Nursing
Clinics of North America.Accepted for Publication inDecember2016issue.
Tariman, J.D.,& Dhorajiwala, S. (2016).Genomic variantsassociated withcancer-related
fatigue: Asystematicreview.Clinical Journal of Oncology Nursing, 20(5), 537-546.
Kurtin, S., Colson, K.,Tariman, J.D., Faiman, B, Finley-Oliver, E., & The IMF Nurse Leadership
Board. (2016). Adherence, persistence, and treatment fatigue in multiple myeloma.Journal of
the Advanced Practitioner in Oncology,7(Suppl1), 71-77.doi: 10.6004/jadpro.2016.7.2.16
Jones,GK.A., &Tariman, J. D.(2016). Effective transitional therapy for adolescent and young
adult cancer patients: An integrative literature review.Clinical Journal of Oncology Nursing,
20(4), 391-396.
Lee, Y.M.,Florez, E.,Tariman, J., McCarter, S., & Riesche, L. (2015). Factors related to sexual
behaviors and sexual education programs for Asian-American adolescents.Applied Nursing
Research, (15)00112-3, S0897-1897. doi: 10.1016/j.apnr.2015.04.015.
Miceli, T. S., Colson, K., Faiman, B. M., Miller, K.,Tariman, J. D., & the IMF Nurse Leadership
Board. (2011). Maintaining bone health in patients with multiple myeloma: Survivorship care
plan of the IMF Nurse Leadership Board.Clinical Journal of Oncology Nursing, 15(Suppl),9-23.
Bilotti, E., Faiman, B. M., Richards, T. A.,Tariman, J. D., Miceli, T. S., Rome, S. I., & the IMF Nurse
Leadership Board. (2011). Survivorship care guidelines for patients living with multiple myeloma:
Consensus statements ofthe IMF Nurse Leadership Board.Clinical Journal of Oncology Nursing,
15(Suppl), 5-8.
Faiman, B. M., Mangan, P., Spong, J.,Tariman, J. D., &the IMF Nurse Leadership Board. (2011).
Renal complications in multiple myeloma and related disorders: Survivorship care plan of the
IMF Nurse Leadership Board.Clinical Journal of Oncology Nursing, 15(Suppl),66-76.
8
Colson, K., Doss, D.S., Swift, R., &Tariman, J.(2008). Expanding role of bortezomib in multiple
myeloma: Nursing implications.Cancer Nursing, 31(3), 239-49.
Tariman, J. D., Love, G., McCullagh, E. J., Sandifer, S., IMF Leadership Board. (2008). Peripheral
neuropathy associated with noveltherapies in patients with multiple myeloma: Consensus
statement of the IMF Nurse Leadership Board.Clinical Journal of Oncology Nursing, 12(3, Suppl),
29-35.
Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B., theIMF NurseLeadership
Board. (2008). Management of side effects of novel therapies for multiple myeloma.Clinical
Journal of Oncology Nursing, 12(3, Suppl),9-12.
Faiman, B., Bilotti, E., Mangan, P.A., Rogers, K., & theIMF Nurse Leadership Board. (2008).
Steroid-associated side effects in patients with multiple myeloma: Consensus statement of the
IMF Nurse Leadership Board.Clinical Journal of Oncology Nursing, 12(3, Suppl),53-62.
Miceli, T., Colson, K., Gavino, M., Lilleby, K., & theIMF Nurse Leadership Board. (2008).
Myelosuppression associated with novel therapies in patients with multiple myeloma:
Consensus statement of the IMF Nurse Leadership Board.Clinical Journal of Oncology Nursing,
12(3, Suppl),13-19.
Rome, S., Doss, D.S., Miller, K., Westphal, J., &theIMF Nurse Leadership Board. (2008).
Thromboembolic events associated with novel therapies in patients with multiple myeloma:
Consensus statement of the IMF Nurse Leadership Board.Clinical Journal of Oncology Nursing,
12(3, Suppl),21-27.
Smith, L.C.,Bertolotti, P., Curran, K., Jenkins, B., & theIMF Nurse Leadership Board.(2008).
Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma:
Consensus statement of the IMF Nurse Leadership Board.Clinical Journal ofOncology Nursing,
12(3, Suppl),37-51.
Tariman, J. D.(2007). Lenalidomide: A promising novel agent for patients with relapsed and/or
refractory multiple myeloma.Clinical Journal of Oncology Nursing,11, 569-74.
Rodriguez, A.,Tariman, J. D., Enecio, T., Estrella, M. E. (2007).The role of high dose
chemotherapy supported by hematopoietic stem cell transplantation in patients with MM:
Implications for nursing.Clinical Journal of Oncology Nursing, 11, 579-89.
Tariman, J. D.(2007). Currenttherapies for multiple myeloma.Journal of Infusion Nursing,
30(2), 113-18.
Tariman, J. D.& Estrella, E. (2005).The changing treatment paradigm in patients with newly
diagnosed multiple myeloma: Implications to nursing practice.Oncology Nursing Forum,31,
E127-E138.
Colson, K., Doss, D. S., Swift, R.,Tariman, J.,& Thomas, T. E. (2004). Bortezomib, a newly
approved proteasome inhibitor for the treatment of multiple myeloma: Nursing implications.
Clinical Journal of Oncology Nursing, 8(5),473-80.
9
Tariman, J. D.(2004). Clinical applications of magnetic resonance imaging in patients with
multiple myeloma.Clinical Journal of Oncology Nursing, 8,317-20.
Tariman, J. D.(2003). Understanding novel therapeutic agents for multiple myeloma.Clinical
Journal of Oncology Nursing, 7,521-28.
Tariman, J. D.& Lemoine, C (2003). Bortezomib.Clinical Journal of Oncology Nursing, 7,687-89.
Tariman, J. D.(2003). Thalidomide: Current therapeutic uses and management of its toxicities.
Clinical Journal of Oncology Nursing, 7,143-47.
Books
Tariman, J. D.& Faiman, B. (2015).Multiple Myeloma: A Textbook for Nurses(2nd ed.).
Pittsburgh, PA: Oncology Nursing Society Publishing Division.
Tariman, J. D.(2010).Multiple Myeloma: A Textbook for Nurses. Pittsburgh, PA: Oncology
Nursing Society Publishing Division.
Book chapters
Tariman, J. D.,Faiman, B. (2015). Chapter 1: Introduction.In. J. D. Tariman & B. Faiman.Multiple
Myeloma: A Textbook for Nurses,2nd edition, Pittsburgh, PA: ONS Publishing Division.
Tariman, J. D.(2015). Chapter 12: Clinical trials.In. J. D. Tariman & B. Faiman.Multiple
Myeloma: A Textbook for Nurses,2nd edition, Pittsburgh, PA: ONS Publishing Division.
Tariman, J. D.& Faiman, B.(2011). Chapter 61: Multiple Myeloma.In. C.H. Yarbro, M.H. Frogge,
& M. Goodman.Cancer Nursing Principles and Practice,7thed. Sudbury, MA: Jones and Bartlett
Publishers. Pp. 1513-1545.
Tariman, J. D.(2010). Chapter 1: Introduction.In. J. D. Tariman.Multiple Myeloma: A Textbook
forNurses,Pittsburgh, PA: ONS Publishing Division. Pp. 1-7.
Tariman, J. D.(2010). Chapter 14: On the horizons: Future considérations.In. J. D. Tariman.
Multiple Myeloma: A Textbook for Nurses,Pittsburgh, PA: ONS Publishing Division. Pp. 267-277.
Tariman, J. D.(2005). Chapter 59: Multiple Myeloma.In. C.H. Yarbro, M.H. Frogge, & M.
Goodman.Cancer Nursing Principles and Practice,6thed. Sudbury, MA: Jones and Bartlett
Publishers. Pp. 1460-1489.
Doctoral Dissertation
10
Tariman, J. D. (2011). Treatment Decision Making in Older Adults Newly Diagnosed with
Myeloma.University of Washington, Ph.D. (180 p) (doctoral dissertation-research) ISBN: 978-1-
124-60389-6.
Refereed Published Abstractsof Original Research
Tariman, J. D.(2013). Treatment, prognosis and self-care are top information need priorities of
older adults newly diagnosed with active Myeloma(Abstract #352).Clinical Lymphoma,
Myeloma & Leukemia ,13,26.
Tariman, J. D.(2013). Older adults newly diagnosed with myeloma want to participate in
treatment decision making(Abstract #351).Clinical Lymphoma, Myeloma & Leukemia ,13,26.
Faiman, B.,Tariman, J., Bilotti, E., Doss, D., Miller, K, Richards, T., Gleason, C. andThe
International Myeloma Foundation Nurse Leadership Board. Health maintenance and
preventive care practices of myeloma survivors (Abstract #339). Clinical Lymphoma, Myeloma &
Leukemia ,13,25.
Heuck, C., Mehta, J.,Tariman, J.,Pulliam, N., Yu, Y., Bhagat, T., et al. (2010). Epigenomic profiling
of multiple myeloma shows widespread stage specific alterations in DNA methylation that occur
early during myelomagenesis [Abstract #784].Blood,116(21),344.
Tariman, J. D., Berry, D. L., Cochrane, B., Doorenbos, A., & Schepp, K. (2010). Treatment
decision-making in older adults newly diagnosed with myeloma: A Preliminary analysis.
Communicating Nursing Research(CD-ROM). Poster presentation at WIN Conference 2010.
Tariman, J.D.(2009). Preferred and actual level of participation during treatment decisions in
persons with cancer: A systematic review.Communicating Nursing Research(CD-ROM). Poster
presentation at WesternInstitute ofNursingConference 2009.
Tariman, J. D.(2009). A proposed theoretical model of decision making participation, decisional
conflict, regret, satisfaction, and QOL in adults with cancer.Communicating Nursing Research
(CD-ROM). Poster presentation at WIN Conference 2009.
Moran, D., Bertolotti,P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B.,Tariman, J. D.,et
al.(2009). Long-term care guidelines for myeloma patients [Abstract # 30].Clinical Lymphoma &
Myeloma,9, S6-S7.
Tariman, J. D.(2008). Decision-making in oncology settings: A concept analysis.Communicating
Nursing Research, 41,336.
Tariman, J.D., Berry, D.L., Halpenny, B., & Wolpin, S. (2008). Validation and testing of the
Acceptability E-scale.Communicating Nursing Research, 41,372.
Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B.,Tariman, J. D.,et al.(2007).
Nursing guidelines for enhanced patient care [Abstract # PO-1102].Haematologica,92(6Suppl),
211.